Reaction
Peripheral Artery Occlusion reporting signals
As of the last recalculation, Peripheral Artery Occlusion appears in 1,381 FAERS reports alongside 28 co-occurring drug terms. The strongest observed disproportionality signal is NILOTINIB (PRR 33.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Nilotinib | 63 | 33.7 | 33.8 |
| Baricitinib | 13 | 20.5 | 20.5 |
| Inclisiran | 9 | 17.0 | 17.0 |
| Felodipine Extended-Release Tablets | 11 | 14.7 | 14.7 |
| Felodipine | 11 | 14.7 | 14.7 |
| Clopidogrel Bisulfate | 90 | 14.1 | 14.1 |
| Heparin Sodium | 11 | 12.1 | 12.2 |
| Ticagrelor | 24 | 11.5 | 11.5 |
| Linagliptin | 13 | 10.8 | 10.8 |
| Clopidogrel | 129 | 10.7 | 10.7 |
| Alteplase | 10 | 10.1 | 10.1 |
| Pitavastatin Calcium | 6 | 8.9 | 8.9 |
| Bosutinib | 5 | 8.4 | 8.4 |
| Empagliflozin | 34 | 7.8 | 7.8 |
| Rivaroxaban | 97 | 7.5 | 7.5 |
| Alirocumab | 12 | 7.3 | 7.3 |
| Gemcitabine Hydrochloride | 23 | 6.6 | 6.6 |
| Gemcitabine | 17 | 6.6 | 6.6 |
| Acalabrutinib | 5 | 6.2 | 6.2 |
| Risankizumab-Rzaa | 32 | 6.0 | 6.0 |
| Ranolazine | 4 | 5.8 | 5.8 |
| Dasatinib | 12 | 4.9 | 4.9 |
| Remdesivir | 4 | 4.5 | 4.5 |
| Pazopanib Hydrochloride | 8 | 4.5 | 4.5 |
| Sacubitril And Valsartan | 33 | 4.4 | 4.4 |
| Patiromer | 3 | 3.3 | 3.3 |
| Evolocumab | 26 | 2.4 | 2.4 |
| Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride | 5 | 2.4 | 2.4 |